Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies

NCT02504346 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

NCT NCT02504346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02504346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies
Lead sponsor
Oslo University Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2015
Completion date
June 30, 2023
Enrollment
200 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, targeted therapy